Please assess the completion status of the following clinical trial:

Trial Title: A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of T2DM~* Must provide written informed consent~* Body mass index greater than (\>) 27 and less than (\<) 40 kg/m\^2, inclusive~* Venous access suitable for multiple cannulations~* Vital signs within normal specified ranges~* Females must be non-lactating and non-childbearing potential~* Males must practice 2 effective contraceptive measures if sexually active~Exclusion Criteria:~* Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product~* History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs~* History of cancer within the last 10 years, with the exception of non-melanoma skin cancer~* Any clinically important illness (except for T2DM), medical/surgical procedure, or trauma within 4 weeks prior to dosing~* Fasting glucose greater than or equal to (\>=) 200 mg/dL~* Positive Hepatitis B, Hepatitis C or human immunodeficiency virus test or use of antiretroviral medications at screening.~* Concurrent or previous use of a glucagon-like peptide 1 receptor agonist~* Current or previous use of systemic corticosteroids within the past 28 days prior to screening~* Use of any medicinal products or herbal preparations licensed for control of body weight or appetite is prohibited.~* Known or suspected history of alcohol or drug abuse within the past 3 years.~* Positive drug screen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo (matched to either 100 micrograms \[mcg\], or 150 mcg or 200 mcg or 300 mcg of MEDI0382) subcutaneously (SC) once daily from Day 1 to Day 7 (Cohort 1); or Day 1 to Day 11 (Cohort 2); or Day 1 to Day 15 (Cohort 3); or Day 1 to Day 41 (Cohort 4); or Day 1 to Day 22 (Cohort 5); or Day 1 to Day 17 (Cohort 6).
- Cohort 1: MEDI0382 100 mcg (Type: EXPERIMENTAL): Participants will receive MEDI0382 100 mcg SC once daily from Day 1 to Day 7.
- Cohort 2: MEDI0382 150 mcg (Type: EXPERIMENTAL): Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4) and thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 7 days (Day 5 to Day 11).
- Cohort 3: MEDI0382 200 mcg (Type: EXPERIMENTAL): Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 7 days (Day 9 to Day 15).
- Cohort 4: MEDI0382 200 mcg (Type: EXPERIMENTAL): Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 4 days (Day 9 to Day 12), then a further MEDI0382 200 mcg SC once daily for 28 days (Day 13 to Day 40) at home-dosing; followed by MEDI0382 200 mcg SC once daily for 1 day in hospital (Day 41).
- Cohort 5: MEDI0382 300 mcg (Type: EXPERIMENTAL): Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 5 days (Day 6 to Day 10); then a second up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 11 to Day 15); followed by third up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 16 to Day 22).
- Cohort 6: MEDI0382 300 mcg (Type: EXPERIMENTAL): Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 6 to Day 10); followed by a second up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 11 to Day 17).

Based on this trial design, predict the completion outcome and termination type (if applicable).